Skip to content

Patient preferences for treatment of Hidradenitis suppurativa

Patient preferences for treatment of Hidradenitis suppurativa

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00018787
Enrollment
300
Registered
2019-09-06
Start date
2019-11-07
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

L73.2

Interventions

Group 1: Observational study: Patients with Hidradenitis suppurativa will once complete an computer-based questionnaire on sociodemographic and socioeconomic characteristics, disease characteristics,

Sponsors

Universitätsmedizin Göttingen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Dated and signed consent form - Patients with physician-diagnosed Hidradenitis suppurativa, irrespective of disease severity or current or former therapy - Age = 18 Jahre - Ability to understand discrete choice experiments

Exclusion criteria

Exclusion criteria: Any member of the study team who is directly or indirectly involved in the study

Design outcomes

Primary

MeasureTime frame
The objective of the study is the identification of patient preferences for outcome and process attributes in the treatment of Hidradenitis suppurativa with medical (antibiotics, adalimumab) and surgical therapies.

Secondary

MeasureTime frame
Subgroup analysis of patient preferences with regard to patient and disease characteristics

Countries

Germany

Contacts

Public ContactRotraut Mößner

Universitätsmedizin Göttingen

rmoessn@gwdg.de0551-39-66401

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026